Skip to content
Type 2 Diabetes & Cardiometabolic Care: Wearables, AI & GLP-1s
Upcoming Reg. Closed Past Event

Type 2 Diabetes & Cardiometabolic Care: Wearables, AI & GLP-1s

The rise of wearables, GLP-1s, and AI is reshaping treatment for Type 2 diabetes, weight loss, and metabolic disease. We have more information and resources than ever to treat these conditions, but population health outcomes continue to lag. At the same time, rising healthcare costs and point-solution fatigue

The rise of wearables, GLP-1s, and AI is reshaping treatment for Type 2 diabetes, weight loss, and metabolic disease. We have more information and resources than ever to treat these conditions, but population health outcomes continue to lag. At the same time, rising healthcare costs and point-solution fatigue

The rise of wearables, GLP-1s, and AI is reshaping treatment for Type 2 diabetes, weight loss, and metabolic disease. We have more information and resources than ever to treat these conditions, but population health outcomes continue to lag.

At the same time, rising healthcare costs and point-solution fatigue continue to challenge patients, employers, health plans, and other organizations responsible for paying for care.

During this webinar, leaders from across the healthcare industry will explore how cardiometabolic care is evolving, what approaches are delivering meaningful clinical and financial outcomes, and how employers, health plans, and providers should think about treatment strategy going forward.

Expect us to cover:

1. How Cardiometabolic Care Is Evolving

  • How have GLP-1s, wearables, AI, and continuous monitoring changed the way we think about Type 2 diabetes and cardiometabolic disease?
  • What have we learned about what works and what does not?
  • What does a durable, long-term approach to cardiometabolic care look like?

2. Cost, Coverage and GLP-1 Strategy

  • Why has cardiometabolic health become such a major cost priority for employers and health plans?
  • How should organizations think about the long-term role and coverage of GLP-1s?
  • What clinical and financial outcomes should be considered when evaluating whether these treatments are delivering value?

3. Measuring Outcomes and ROI

  • Which clinical, financial, and engagement metrics matter most when evaluating cardiometabolic programs?
  • How long should employers and health plans expect it to take before meaningful ROI becomes visible?
  • How should leaders distinguish between short-term results and durable outcomes?

4. Payment Models and Accountability

  • What payment models work best for cardiometabolic care?
  • Where do performance guarantees and risk-sharing arrangements make sense?
  • What questions should employers and health plans ask vendors before adopting a new solution?

5. Keeping Patients and Members Engaged

  • What makes patients stay engaged in treatment over the long term?
  • How should technology support the patient experience without adding complexity?
  • What have clinicians and benefits leaders learned about designing programs around real patient needs?

Share this event

More Webinars

View all →